PTC Therapeutics has sold its rare pediatric disease priority review voucher (PRV) for $150 million, following FDA approval ...

The waiting time for Latin American patients with cancer, central nervous system disorders or rare diseases can take up to ...

A report from DelveInsight highlights over 20 companies developing 22 treatments for myotonic dystrophy, with progress in ...

Olverembatinib, developed by Ascentage Pharma, will be added to China’s National Reimbursement Drug List (NRDL) starting next ...

The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa ...

The first iteration of the European Shortages Monitoring Platform (ESMP) has gone live. Using this version of the ESMP, marketing authorization holders (MAHs) can submit data to routinely report ...

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for ...

Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of ...

San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, ...

The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of ...

The US Food and Drug Administration (FDA) yesterday announced its Fiscal Year 2025 Generic Drug User Fee Amendments (GDUFA).

Munich, Germany headquartered contract development and manufacturing organization (CDMO) Adragos Pharma has acquired Baccinex ...